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1. Introduction
The Acute lymphoblastic leukemia (ALL), it produced as a result of a process of malignant
transformation of a progenitor lymphocytic cell in the B and T lineages. In ALL, the majority
of the cases, the transformation affects the B lineage cells. Leukemia and other cancers share
biological characteristics, as clonality. The molecular alterations that are required for the de‐
velopment of a malignant disease is a rare phenomenon when one considers the large number
of target cells susceptible to this condition, in other words, a single genetic change rarely be
sufficient for developing a malignant tumor. This means that a small percentage of people (1%)
who develop malignant hematological disease, probably only 1 cell mutated in a critical gene
for the proliferation, differentiation and survival of progenitor cells. There is evidence sup‐
porting a sequential multistep process, of alterations in several oncogenes in tumor suppressor
genes or microRNA genes in cancerigen cells.
Genes involved in leukemia
Most of what is known of the influence of some mutant genes of the origin of leukemia, derived
from studies in molecular virology, in the gene transfection, and in the generation of leukemia
in-vivo in transgenic mice. These studies are based on bacterial DNA recombinant methods.
Most of the mutations in leukemia are acquired and occur in the lymphoid cell progenitor, less
frequently (1% to 5% of leukemia) the mutated genes are inherited, this involved a numerical
chromosome abnormality, for example: constitutive trisomy 21.
Genetic factors of acute leukemia have been extensively studied. The results of studies of gene
expression analysis of high resolution whole genome, copy number alterations of DNA, loss
of heterozygosity epigenetic changes and whole genome sequencing, have allowed the rec‐
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ognition of new genetic alterations, so that virtually all patients with ALL can be classified
according to the specific genetic abnormality. This information has increased our knowledge
of leukemogenesis, the prognosis and has served as the basis for the development of the target
therapy. However, the understanding of how genetic alterations collaborate to induce leuke‐
mic transformation remains unclear.
The altered genes in the leukemia can be result in loss or gain of the function through several
mechanisms, for example: abnormal recombination (chromosomal, translocation, inversion,
insertion) loss of genetic material (deletion) gain of genetic material (duplication) point mu‐
tation and the presence additional copies of certain chromosomes as in the case of hyperdi‐
ploidy; previous alterations favoring the activation of oncogenes, this encode proteins that
control cells proliferation, apoptosis or both.
The advances in the conventional cytogenetic techniques, as the fluorescence in situ hybridi‐
zation, have shown the chromosomal rearrangements. In this sense, recently has been reported
that the incidence of chromosomal change is related with the age, so the translocation t(9;22)
(q34;q11) increases in each successive decade, up to 24% between the 40-to 49 years old, the
t(4;11) (q21;q23) and t(1;19) (q23;q13) are rare in patients older than 60 years old, but t (8;14)
(q24;q32) and t(14;18)(q32;q21) increased with age. The hiperdipoidia occurs in 13% of patients
under 20 years old and only 5% of elderly patients. The hypodiploidy and complex karyotype
(presence of more than 2 chromosomal abnormalities) also increase with age of 4% in the range
of 15 to 19 years old to 16% older than 60 years old.
When an oncogen is activated by mutation, encoded protein is structurally modified so that
enhances its transforming activity, thus remains on active status, continuously transmitting
signals through the binding of tyrosine and treonina cinasa. These signals induce cell growth
continued incessant. This mechanism of activation of ocogenes is more evident in others forms
of leukemia, for example: severe myeloblastic leukemia and other myelodysplastic syndromes
where the genes NRAS are mutated. There are mutations that suppress the function and are
observe in tumor suppressor genes such as TP53, however, less than 3% of patients with ALL
are TP53 mutations, although all cells have a resistance abnormal apoptosis induced by lack
of significant proportion of p53, which is explained in large part by epigenetic medications.
By other hand, some authors have found alterations in the number of copies (ANCs) to 50
recurrent regions in ALL, some are really small and they have less than 1 Mb, however occur
in genes encoding regulatory proteins of normal lymphoid development in 40% of cases of
ALL progenitors B. The target most common are lymphoid transcription factor PAX5 that have
deletions or amplifications until 30% of cases with ALL-B, also found in genes ANCs of tran‐
scription factor IKZF1 the IKZF3, EBF1, LEF1 and TCF3, RAG1 and RAG2.
Another important point, is the dihydrofolate reductase (DHFR) gene amplification has been
considered as the most relevant in the ALL, this amplification produce cytogenetic abnormal‐
ities evident as the amplified of high DNA segment that included some hundreds of kilobases.
The ALL of T-cell type represents about 10% to 15% of the ALL in adults and the 25% in children
and their clinical behavior is the most aggressive, the patients have a higher percentage of
failure of remission induction, relapse rate is also higher, and had infiltration at central nervous
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system compared with B-cell ALL. In this sense, is known that the oncogenes and tumor sup‐
pressor genes are implicated in ALL-T are: c-MYC, NOTCH, LMO1 / 2, LYL1, TAL1 / 2, Hox11
and HOX11L2. It is clear that NOTCH activated is able to induce leukemogenesis of T cell and
this is critical for the progression to ALL-T. Family members of NOTCH are transmembrane
receptors that are involved in controlling the differentiation, proliferation and apoptosis in
several cell types including T cells. The binding of its ligand to the extracellular domain, re‐
sulting in cleavage of the intracellular domain of NOTCH, this reaction is catalyzed by γ-
secretase complex, and the intracellular domain free of translocase to the nucleus, that
regulates transcription of genes regulated by NOTCH.
The NOTCH target genes are mainly cyclina D1 and c-Myc. Both NOTCH as c-MYC regulate
cell cycle progression by inducing expression of cyclins and reduced expression of p27. An
important aspect is that NOTCH is able to inhibit apoptosis induced by p53 allowing the tumor
regression. In the development of ALL-T there is strong evidence of pro-oncogenic function
of signals transduced by NOTCH, and that modulates the activity of downstream signaling
pathways, through transcriptional regulation of their target genes. Is possible regulators of
signaling downstream of NOTCH especially in murine models are some intermediate signal‐
ing routes as: phosphatidylinositol 3-kinase (PI3K), Akt / protein kinase B, extracellular signal-
regulated kinase-1/2, and nuclear factor kB. In general, the products of oncogenes can be
classified into six categories: transcription factors, chromatin remodeling, growth factors,
growth factor receptors, signal transducers, and finally regulators of apoptosis. Transcription
factors generally require interacting with other proteins to act, for example: Fos transcription
protein dimerizes with the transcription factor Jun to form the AP1 transcription factor is really
a complex, and this increases the expression of several genes control cell division, all they have
been involved in the development of leukemia.
Aberrant methylation of CpG sites in promoter regions of genes has been identified in ALL
cell lines, to respect it is important to note that methylation of CpG dinucleotides in position
near the site of transcription initiation can silence gene expression, hypermethylation of tumor
suppressor genes and hypomethylation of oncogenes can lead to various forms of cancer.
Other mechanism important in the development of the ALL is the angiogenesis and signal
transducers on the binding of tyrosine kinase receptors, finally the molecules regulators of the
apoptosis, where the BCL2 gene encodes for a cytoplasmic protein that is localized in the
mitochondria and increases the survival of the cell by inhibiting apoptosis.
Secondary leukemias
Secondary hematological malignancies are a serious complication of cancer treatment. They
usually manifest as acute leukemias and myelodysplastic syndromes. This also touch the item
on secondary leukemias and its frequency is high and has increased possibly due to increas‐
ingly frequent use of genotoxic agents and by increased survival to other types of cancer. So,
learn more about these could eventually help reduce its appearance. It is known that this type
of leukemia may arise as a result to exposure to cytotoxic treatments (side effects of genotox‐
icity) and / or radiation therapy and as a result of other blood disorders; probably as a result
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of environmental or genetic causes. In particular in this we will focus more on the former. In
most cases it is suggested that the mechanism of leukemogenesis is associated with DNA
damage of hematopoietic cells from bone marrow by agents such as those used in chemother‐
apy. Although the majority of secondary leukemias are acute myeloid leukemia (AML) has
been reported cases of lymphoid leukemia and chronic myeloid leukemia (CML) associated
with chemotherapy treatments. Finally, we intend to touch points as the classification of sec‐
ondary leukemias, its relationship to chemotherapeutic agents and ionizing radiation, etiolo‐
gy, individual susceptibility, pathogenesis, and treatment as well as their behavior in infants
and adults.
In this way one can conclude that the pathophysiology of ALL involved mechanisms genetic
and environmental complex at different levels, and also have a close and complex relationship.
The key features in the pathophysiology of the ALL is its monoclonal origin, uncontrolled cell
proliferation by sustained self-stimulation of their receptors for growth, no response to inhib‐
itory signals, and cellular longevity conditioned by decreased apoptosis.
Acute lymphoblastic leukemia (ALL) is the result of a process of malignant transformation of
progenitor cell lineage of the B and T lymphocytes. (Pui et al, 2011) In most cases of ALL, this
transformation affects B lineage cells. (Heltemes et al, 2011)
In the last 3 decades, there has been a significantly improvement in treatment outcome of ALL
in children, 70% to 80% of children can get cured of their disease, a situation that is different
in adults with ALL, since only 30% -35% of them may heal. (Sotk et al, 2000; Mullighan and
Downing, 2009)
The required molecular alterations, for the development of malignant disease, are a rare phe‐
nomenon, when it is considered the large number of target susceptible cells to such alteration
(Greaves, 2002) ie, a single genetic change is unlikely to be sufficient for the development of a
malignant tumor (Croce, 2008), this means that in a very low percentage of people (1%) is
developed a hematologic malignancy, only 1 cell will likely experience a mutation in a critical
gene for proliferation, differentiation and survival of progenitor cells (Greaves, 2002), that`s
what we mean when we mention the monoclonal origin of cancer.
It is important to mention that when we refer to the origin of cancer, in this cases ALL, ref‐
erence is made to the terms: Cell Origin and Stem Cell Cancer. Actually, the concept im‐
plies that normal cells of distinct origin acquire the first mutation(s) to promote cancer, ie,
that is the cell that will initiate the cancer, while the cancer stem cell will disseminate it
(figure 1). (Visvader, 2011)
Malignant diseases, including acute leukemias, show a marked heterogeneity in cellular mor‐
phology, rate of proliferation, genetic lesions and, as a result, the response to treatment. The
molecular mechanisms, underlying the heterogeneity of malignant neoplasia, are important
points in the study of the cancer’s biology. (Visvader, 2011) Above mentioned alterations may
be due to somatic mutations, although alterations in the germline may predispose to familial
(or hereditary) cancers. (Croce, 2008)
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There is growing evidence that supports a multi-step process in leukemogenesis, ie, sequential
steps and serial number of alterations in oncogenes, tumor suppressor genes, or microRNA genes
in cancer cells. (Greaves, 2002; Croce, 2008) Oncogenes are dominant genes that once mutated,
from a normal cellular gene (proto), encode abnormal proteins that cannot control cell prolifera‐
tion, apoptosis, or both, thereby contributing to cancer development. (Pierce, 2009)
A suppressor gene normally inhibits cell division, and favors the growth of cancer when both
alleles are mutated, i.e., they are recessive mutations, where the lack of function of both alleles
is promoting the development of malignancy. (Pierce, 2009)
Unlike the genes involved in cancer development, microRNA genes do not encode proteins,
their products are small RNA molecules (single strands of 21 to 23 nucleotides) that recognize
and bind a nucleotide sequence of messenger RNA (mRNA), to the complementary microRNA
sequence, and thus blocking the translation of protein from mRNA; then, their function is to
regulate gene expression. (Calin et al., 2002; Croce, 2008)
2. Genes involved in the leukemias
Much of what we know about the great influence of certain mutant genes, in the origin of
leukemia, is derived from mouse transgenesis studies in molecular virology, with gene trans‐
fection and the generation of leukemia in vivo. These studies are based on bacterial recombinant
DNA methods. (Pui et al, 2011)
This knowledge has increased our understanding of leukemogenesis and prognosis, and ad‐
ditionally has served as foundation for the development of targeted therapy. However, the
comprehension of how genetic alterations that collaborate to induce leukemic transformation
is not clear yet.(Pui et al, 2011)
 
 
 
   
Stem Cell 
Common progenitor 
Committed progenitor 
Matured cells 
Figure 1. Cell origin and evolution of a cancer stem cell (modified of Visvader, 2011)
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Most mutations in leukemia are acquired, and occur de novo in the lymphoid progenitor cells,
less frequently (1% to 5% of leukemias) the mutated genes are inherited (vgr, p53, DNA ligase),
or a numeric chromosomal abnormality is involved, for example constitutive trisomy 21.
(Greaves, 2002)
Acute leukemias are the most studied malignant disorders from a genetic standpoint, the re‐
sults of whole-genome studies, e.g.: gene expression analysis of high-resolution, genome-wide
alterations in DNA copy number variation (CNA), loss of heterozygosity, epigenetic changes,
and complete genome sequencing have favored the recognition of new genetic alterations,
then virtually all patients with LLA can be classified according to the specific genetic abnor‐
mality, as shown in Figure 2, which is evident in children with ALL the high frequency of
genetic abnormalities. (Mullighan et al, 2007; Pui et al, 2011)
Figure 2. Frequency of genetic abnormalities in childrenwith ALL. (modified of Puiet al, 2011.)
As discussed previously, the altered genes in leukemia can result in loss or gain of function,
and this is achieved through various mechanisms, for example, abnormal recombination
(chromosomal translocation, inversion, or insertion), loss of genetic material (deletion), gain
of genetic material (duplication), or mutation. Also can be present additional copies of certain
chromosomes, as in the case of hyperdiploidy. With these chromosomal alterations, the acti‐
vation of oncogenes is favored. Oncogenes can be activated by: chromosomal rearrangements,
gene mutation and gene amplification. (Croce, 2008)
i. The demonstration of chromosomal rearrangements have been evidenced by im‐
proved conventional of cytogenetic study. The standard analysis can detect primary
chromosomal abnormalities in more than 75% of all cases. (Liang et al, 2010)
Recently, it was reported that the incidence of chromosomal alterations is associated with age.
(Moorman et al, 2010) In fact, age is a determining factor in the prognosis and treatment out‐
come for patients with ALL. In long term survival, the rates are close to 80% in children under
5 years of age, but will decrease to 50% or 60% in adolescents and young adults, and approx‐
imately 30% in adults of 45 to 54 years, but rarely exceed 15% in older adults. The Philadelphia
chromosome (Ph) is the most common cytogenetic abnormality associated with ALL in adults.
(Zuo et al, 2010; Lee et al, 2011)
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The Philadelphia chromosome positive (Ph+) ALL is a product of reciprocal translocation be‐
tween the long arm of chromosome 9(q34), where the oncogene ABL1 is located, and the long
arm of chromosome 22(q11), where the BCR gene lies, leading to the formation of the BCR-
ABL1 chimeric protein (Figure 3), and as a result of this fusion the Bcr-Abl tyrosine kinase,
constitutively active, is produced, which is responsible for the acute and chronic leukemia
forms. (Martinelli et al, 2009)
Figure 3. Philadelphia chromosome translocation (translocation between 9 and 22 chromosomes). (modified of Satter‐
and James, 2003)
This alteration is relatively rare (approximately 5%) in infants with ALL, but not in adults
where its frequency range between 20% and 30%, it was the first known cytogenetic abnor‐
mality associated with chronic myeloid leukemia (CML) and Ph+ALL.
Despite the Ph+ ALL occurs in only about 5% of patients under 20 years of age, the incidence
increases to 33% in patients over 40 years and it reaches 49% in patients over 40 years, to
decrease the incidence to 35% in patients over 60 years. (Lee et al, 2011)
A significant proportion of patients with ALL Ph+ (approximately 85%), and high-risk ALL
without BCR-ABL1 fusion (~28%), have IKZF1 gene deletion, and both situations are associated
with adverse prognosis. (Martinelli et al, 2009; Cazzaniga et al, 2011)
The gene IKZF1 is located on 7p12, and encodes the transcription factor Ikaros, which is a
member of the family of transcription factors containing zinc fingers (Martinelli et al, 2009).
Deletion of IKZF1 is not observed in the chronic phase of CML, but is detected in two out of
three samples analyzed during the lymphoid blast crisis. (Mullighan et al, 2009) IKZF1 genomic
alterations, causing loss expression or expression of dominant negative isoforms, are critical
in the pathogenesis of BCR-ABL1 ALL Ph+. (Mullighan et al, 2009)
Almost half of patients with BCR-ABL1 ALL and lymphoid blast crisis CML also harbor de‐
letion of CDKN2A/B and PAX5 genes; approximately 20% of these cases have deletion of the
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three genes. These data support the concept that it is required the alteration of several cellular
pathways to induce the development of ALL. It has been correlated the ALL IKZF1 focal de‐
letion with clinical response to treatment, overall response rate of relapse and disease-free
survival; and it has also been shown that deletion of Ikaros gene represents the most important
prognostic factor so far described, in ALL Ph+.(Mullighanh et al, 2009; Martinelli et al, 2009)
Other chromosomal abnormalities associated with age are the t(4;11)(q21;q23) and t(1;19)
(q23;p13), that are rare in patients older than 60 years of age, but on the other way t(8;14)
(q24;q32) and t(14;18)(q32;q21) increases with age. (Moorman et al, 2010)
The translocation t(4;11)(q21;q23) leads to the formation of the MLL-AF4 fusion gene, and is
responsible for more than 50% of ALL cases in children younger than 6 months in 10-20% of
older infants, in approximately 2% of children and only 10% of adults with de novo ALL. Chro‐
mosomal abnormality in adults with ALL is considered to be of high risk. (Marchesi et al, 2011)
The gene Mixed Lineage Leukemia (MLL) is frequently involved in hematological malignan‐
cies, particularly acute leukemia, both lymphoblastic and myeloblastic, it is located at 11q23,
and plays an important role in the positive regulation of gene expression during early embry‐
onic development (ie it is a HOX gene) and also in hematopoiesis. (Marchesi et al, 2011)
MLL gene encodes a 500 kD protein containing several conserved functional domains, a target
of proteolytic activity of Caspasa 1, a cleaving protein specialized in N-terminal fragments of
320 kD and C-terminal of 180 kD. This latter is responsible for methyltransferase activity in
lysine 4 of histone H3 (H3K4), which mediates changes in chromatin associated with epigenetic
transcriptional activation. (Milne et al, 2002; Hsieh et al, 2003)
The main chromosomal alterations that may occur with the MLL gene are mainly reciprocal
translocations, causing fusion with other different genes, and partial tandem duplication of
genes. (Schnittger et al, 2000)
Translocations in which MLL gene is involved can result in a chimeric protein, that fuses the
MLL N-terminal with the C-terminal portion of the associated genes; the methyltransferase
domain (SET domain) is invariably lost in the MLL fusion protein. This fusion of genes can
alter normal cellular proliferation and differentiation processes, which favors leukemogenesis.
(Ayton et al, 2001)
MLL gene is a target of about 104 different rearrangements, of which 64 are translocations with
other genes. The proteic products of the fusions are nuclear localization signals, and play an
important function as potent transcription factors. (Meyer et al, 2009)
Genes that most commonly fuses with MLL gene are, in order of frequency: AF4, AF9, ENL,
AF10, AF6, ELL, and AF1P. The leukemias that express the fusion gene MLL-AF4 are diagnosed
primarily as pro-B, in pediatric and adult patients, while the fusion with genes AF9, AF6, or
AF10 are common in AML subtypes myelomonocytic or monoblastic variety. (Kohlmann et
al, 2005; Moriya et al, 2012)
The t(1;19)(q23;p13) is recurrent in children and adults, and results from the fusion of gene
TCF3 transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) locat‐
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ed at 19p13.3, with gene pre-B-cell leukemia homeobox 1 (PBX1), located at 1q23.3, the fu‐
sion gene TCF3 (E2A)-PBX1 encodes a chimeric protein with transforming properties. (Garg
et al, 2009)
The gene encoding E2A transcription factors E12 and E47 binds enhancer elements of the
gene  of  κ  light  chains  of  immunoglobulins,  as  well  as  some other  gene  regulatory  ele‐
ments. (Garg et al, 2009)
The transcriptional activator domain of the chimeric protein encoded by the fusion gene E2A-
PBX1 is provided by E12/E47, and the DNA binding domain is provided by the (HOX) Home‐
box PBX1, this protein promotes leukemogenesis by activation of several genes that are not
normally expressed in lymphoid tissues. (Garg et al, 2009)
The t(12; 21)(p13, q22) is a consequence of gene fusion ETV6/RUNX1 (also known as TEL/
AML1) and is the hallmark of one of the most common genetic subtypes of ALL of precursor
of B cells in children, in whom is the most common molecular genetic alteration occurring in
20% to 25% of pediatric cases; while in adults this translocation is rare. (Pui et al, 2011)
The current model involves several steps, the fusion of these genes can occur already during
fetal development and is the initial event, but is not sufficient for the neoplastic transformation
(Fuka et al, 2011). Indeed, the development of ALL of infancy B cell lineage involves (at least)
2 genetic events (hits), the first of which often arises in prenatal stage. (Thomsen et al, 2011)
The fusion gene that encodes a chimeric transcription factor, involves the N-terminus of the
protein ETV6 and the most of the RUNX1 protein, it is believed that normally RUNX1 acts as
a modulator of transcription; transcriptional repressor becomes the target genes RUNX1. (Fuka
et al, 2011)
Hyperdiploidy is detected in approximately 25-30% of children with ALL precursor B cells. In
these patients the clinical phenotype is usually associated with low risk and good prognosis.
(Grumayer et al, 2002; Pui et al, 2011) It is interesting to mention that a hyperdiploid karyotype
refers to a higher number of chromosomes than the normal diploid number (e.i., greater than
46 chromosomes), but having a chromosome number that is not a multiple of the haploid number
(23 chromosomes), the modal number can be located between 47-57 chromosomes (Shaffer et
al, 2009). This karyotype arises through a simultaneous gain of multiple chromosomes, from
a diploid karyotype, during a single abnormal cell division. (Grumayer et al, 2002)
The hyperdiploidy occurs in 13% of young adults, and only 5% of elderly patients. The hypo‐
diploidy and complex karyotype (presence of more than 2 chromosomal abnormalities) also
increase with age, from 4% in the range of 15 to 29 years of age and 16% older than 60 years.
(Moorman et al, 2010)
ii. When an oncogene is activated by mutation, the encoded protein is structurally
modified in such a way that increases their transforming activity, ie, remains in the
active state, continuously transmitting signals by binding of tyrosine and threonine
kinase. These signals induce cell growth continued incessant. This mechanism of ac‐
tivation of oncogenes is more evident in other forms of leukemia, for example, AML
and myelodysplastic syndromes (MDS) where the NRAS gene is mutated. There are
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mutations that suppress the function, and it is observed in tumor suppressor genes
such as TP53, however, less than 3% of patients with ALL have TP53 mutations, al‐
though all the cells have abnormal resistance to apoptosis induced by lack of a sig‐
nificant proportion of p53, which is explained in large part by epigenetic. (Zornoza
et al, 2011)
On the other hand, some authors have found change in the number of copies (CNVs) to 50
regions in ALL recurring, some are very small and have less than 1 Mb, however, occur in
genes encoding regulatory proteins of normal lymphoid development up to 40% of cases of
ALL stem B. The most common targets are lymphoid transcription factor PAX5, that can hold
deletions or amplifications in up to 30% of cases of ALL-B, also found CNVs in transcription
factor genes IKZF1, the IKZF3, EBF1 (factor Cell B early), LEF1 and TCF3, and RAG1 and RAG2
genes. (Mullighan et al, 2009)
iii. The most relevant gene amplification in LLA is the dihydrofolatereductase (DHFR).
The amplification of this gene causes evident cytogenetic alterations because the am‐
plified DNA segment may involve several hundred kilobases. (Croce, 2008)
A variety of acute leukemia to consider is the T-cell ALL (ALL-T), it represents about 10% to
15% of ALL in adults and 25% of children. The clinical behavior is more aggressive, patients
have a higher percentage of failure of remission, relapse rate is also higher as well, and the
central nervous system infiltration compared with B-cell ALL type. (Demarest et al, 2011)
Oncogenes and tumor suppressor genes that have been implicated in T-ALL are: c-MYC,
NOTCH, LMO1 / 2, LYL1, TAL1 / 2, Hox11 and HOX11L2. It is clear that activated Notch is able
to induce T cell leukemogenesis and is critical for the progression to T-ALL. (Demarest et al,
2008)
Members of the NOTCH family are transmembrane receptors that are critically involved in
controlling the differentiation, proliferation and apoptosis in several cell types including T
cells. The Notch receptor binding to its ligand exhibits a cleavage site for extracellular ADAM
metalloproteinase, and a cleavage site in the transmembrane region for the γ-secretase, thus
releasing the intracellular domain of Notch, which transmits this signaling to the cell nucleus,
where it is associated with a DNA-binding complex. (Palomero et al, 2006; Chan et al, 2007;
Sanda et al, 2010; Gomez et al, 2012)
Notch signaling cooperates with the signaling of T cell receptors (TCR) to expand the number
of thymocytes undergoing β-selection. Over 50% of T-cell ALL have activating mutations in
Notch1. (Gomez et al, 2012)
NOTCH target genes are mainly cyclin D1 and c-Myc. Both Notch and c-Myc regulates cell
cycle progression by inducing expression of cyclins and reduced expression of p27. An im‐
portant aspect to point out is that Notch is able to inhibit apoptosis induced by p53. When
Notch expression is suppressed, the p53 pathway is activated and leads to tumor regression.
(Demarest et al, 2008; Sanda et al, 2010)
An important aspect of Notch, is that depending on the type of cells, the extracellular en‐
vironment, and the intensity of the signal, Notch can transmit signals as pro-oncogenic or
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tumor suppressor (Leong and Karsan, 2006). In the development of T-ALL there is strong
evidence of pro-oncogenic function of signals transduced by Notch, and that modulates the
activity of downstream signaling pathways,  through transcriptional regulation of its  tar‐
get genes. (Chan et al, 2007)
Possible regulators of signaling downstream of Notch, especially in murine models, are some
intermediate signaling pathways, such as phosphatidylinositol 3-kinase (PI3K), Akt /protein
kinase B, extracellular signal-regulated kinase-1/2, and nuclear factor kB. (Chan et al, 2007)
In general, the products of oncogenes can be classified as described below:
1. Transcription factors: They generally require interacting with other proteins to act, for
example: Fos transcription protein dimerizes with the transcription factor Jun to form the
AP1 transcription factor which is a complex, and this increases the expression of several
genes control cell division.
2. Chromatin remodeling: It plays an important role in the degree of compaction of chro‐
matin and therefore in the control of gene expression, replication and chromosome seg‐
regation, by the action of two types of enzymes: the ATP-dependent enzymes, which have
important role in changing the position of histones, and enzymes that modify N-terminal
tails of histones. (Peterson and Workman, 2000)
Indeed, the epigenetic code is made by the pattern of histone modification, and determines
in this way the interaction between nucleosomes and chromatin-associated proteins,
thereby determining its transcriptional capacity. (Croce, 2008)
On this basis it is important to note that methylation of CpG-dinucleotides in position
near the site of transcription initiation can silence gene expression, hypermethylation of
tumor suppressor genes and hypomethylation of oncogenes can lead to various forms of
cancer. Aberrant methylation of CpG sites in promoter regions of genes has been identified
in ALL cell lines. (Milani et al, 2009)
In this way it has been found some improperly methylated genes that are involved in the
p53 pathway suggesting that despite not having an activating mutation of this gene in
ALL, there is an abnormal function of p53 mediated by epigenetic mechanisms. In fact,
hypermethylation of genes involved in the TP53 pathway is an independent poor prog‐
nostic factor in patients with ALL. (Zornoza et al, 2011)
3. Growth factor receptors: They are altered in many cancers. A deletion of the ligand bind‐
ing domain causes constitutive receptor activation in the absence of ligand binding sites
of interaction by providing cytoplasmic proteins containing the SRC homology domain
binding and other domains, this way deregulates multiple signaling pathways. Vascular
endothelial growth factor (VEGF) regulates hypoxia-dependent control of gene transcrip‐
tion. VEGF activity is mediated by three tyrosine kinase receptors: VEGFR1 (FLT1),
VEGFR2 (Flk1-KDR) and VEGFR3 (FLT4).
The importance of angiogenesis and signaling pathways related to angiogenesis in the
growth and expansion of cells in acute leukemia has been well established. In vitro in the
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leukemic cell, activation of VEGFR1 (FLT1) promotes cell migration and proliferation,
whereas in vivo cells overexpressing FLT-1It accumulate in the bone marrow.
At the same time, the FLT-1 neutralization affects leukemia cell location (now in the bone
marrow of the diaphysis), increased apoptosis, and prevents their departure to other tis‐
sues, which prolongs survival of mice inoculated. (Fragoso et al, 2006)
4. Signal transducers: They on the binding of receptor tyrosine kinases, to appropriate li‐
gand receptor, lead to reorganization and autophosphorylation of tyrosine in the intra‐
cellular portion of the molecules, this increases the activity of the receptor or receptor
interaction promotes intracytoplasmic domain with other proteins such as with the SRC
homology domains. (Croce, 2008)
5. Regulators of apoptosis:Regulators that finally lead to apoptosis, where the BCL2 gene
encodes for a cytoplasmic protein that is localized in the mitochondria and increases the
survival of the cell by inhibiting apoptosis.
Cytogenetics in acute lymphoblastic leukemia
The cytogenetic studies of human neoplasia began in 1960 with the discovery by Nowell
and  Hungerford  of  the  Philadelphia  chromosome in  individuals  with  chronic  myeloge‐
nous leukemia. Thirteen years after, Rowley performed chromosomal banding techniques
and defined the origin of the Philadelphia chromosome as the result of the chromosomal
translocation t(9;22)(q34;q11). (Mitelman et al, 2007; Croce, 2008; Pui et al, 2011; Dowing et
al, 2012) These findings established the beginning for the cytogenetic studies of many sol‐
id and hematologic tumors. Currently, it has been consolidated a public database (Mitel‐
man Database of Chromosome Aberrations and Gene Fusions in Cancer) containing 61,846
reported cases of cytogenetic studies and 975 different gene fusions in diverse human tu‐
mors. (Mitelman et al, 2012)
The ALL is the most common malignancy in pediatric population with a frequency of 19.7%.
It is markedly different from the frequency observed in adults (1.2%). In both groups, the
commitment of B-cell lineage is most frequent than the T-cell lineage. The variety of chromo‐
somal abnormalities observed during the malignant development is also different between
pediatric and adult ALL. The chromosomal abnormalities most frequent in pediatric ALL are
the t(12;21)(p13;q22) with the ETV6-RUNX1 gene fusion (21%) and hiperdiploidy of >50 chro‐
mosomes (19%). In adult ALL the most recurrent chromosomal abnormalities are the t(9;22)
(q34;q11) with the BCR-ABL1 gene fusion (25%) and MLL (11q23) gene fusions (10%). (Dowing
et al, 2012)
The chromosomal translocation t(9;22) fuses the tyrosine kinase ABL1  (v-abl Abelson mur‐
ine leukemia viral oncogene homolog 1) gene located on 9q34 band with the BCR (Breakpoint
Cluster Region) gene situated on 22q11 band raising the 5’-BCR/ABL1-3’ gene fusion. Vari‐
ous forms of this hybrid gene are generated depending on the breakpoint at BCR gene oc‐
curred. The e13a2 and e14a2 BCR/ABL1 transcripts code for a 210 KD protein and the e19a2
produces  a  230  KD protein.  These  isoforms are  related  mainly  to  CML.  The  e1a2  tran‐
script codes for a 190 KD protein which is mostly related to ALL and a trend towards poor‐
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er therapy outcome. Currently,  BCR/ABL1 expressing cells can be selectively killed with
the Imatinib (or STI571, imatinib mesylate, Gleevec or Glivec; Novartis) which inhibits the
excessive tyrosine kinase activity of the hybrid protein. Most of the patients achieve com‐
plete remission with this approach; however, sometimes relapse occurs mainly by muta‐
tions in the ABL1  segment that  render resistance to the Imatinib.  (Mitelman et  al,  2007;
Croce, 2008; Pui et al, 2011; Dowing et al, 2012)
During the progression of the disease multiple genetic alterations accumulate over time being
selected by their potential to give fitness advantage to the new clones. Irrespective which is
the primary change, the most frequent secondary numerical chromosomal changes in ALL are
+X, +6, -7, +8, and +21; whereas, the most recurrent secondary structural aberrations are
dup(1q), i(7q)(q10), and der(22)t(9;22). (Johansson et al, 1994)
Leukemia and immunity
Although little is known about the etiology of leukemia, this has a multifactorial behav‐
ior with risk factors that may contribute to its development such as ionizing radiation, che‐
motherapy and chromosomal abnormalities. (Han et al, 2010) By other hand, there are three
hypotheses one called delayed infection, the second population mixing and the third hy‐
giene hypothesis,  (Strachan, 1989; Kinlen, 1995; Greaves,  2006) the first  two suggest that
the immune system deficiency in an early stage of development can cause an abnormal im‐
mune response to infections which may arise in the development of human beings. Both
hypotheses are similar to third called hygiene hypothesis, which explains an increase in al‐
lergies in Western populations. (Chang et al, 2010) Although most studies support to infec‐
tions and immune system factors in the etiology of ALL, little is known about the role of
genes in this etiology. The relation of immune system in the ALL is a complex process that
involves the interaction of many cells that including leukocytes, epithelial barriers, comple‐
ment proteins,  colexinas,  pentraxins,  cytokines (TNF, IL-1,  chemokines,  IL-2,  IFN type I,
IFN etc.), Th1, Th2, Treg and Th17 cells, CD28, FCGR2, GATA3, STAT4, STAT6 and may
other.  (Chang et al,  2010) Variations in the genes of these cells can affect their develop‐
ment and function in the immune response and therefore it may increase susceptibility to
developing ALL. (Han et al, 2010; Chang et al, 2010) Moreover it was found that the CD47
molecule protects the macrophage leukemic clones to bind to a molecule on the surface of
these cells. The interaction between macrophages and leukemic cells inhibits macrophage
specific  action  which  allows  the  cancer  cell  to  proliferate.  So  that  although  the  macro‐
phage plays an important role in the destruction of cancer cells, leukemic cells with great‐
er metabolic potential, and the potential escapes annihilating the macrophage. (Tesniere et
al,  2008;  Jaiswal  et  al,  2009)  In  the  innate  immune system,  macrophages  and other  im‐
mune cells involved in immune surveillance protect the body permanently cell rate unex‐
pectedly mutates.  In contrast,  the adaptive immune system through T and B cells  upon
activation attempt to destroy leukemic cells; however these also evade cellular immunity.
It has been shown that the human genome sequencing is useful to identify oncogenic mu‐
tations useful in predicting the diagnosis, prognosis and therapeutic choice. What has pro‐
vided important insights into the pathogenesis of leukemias. (Kalender et al, 2012)
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Polymorphisms environmental in leukemia
Although the clinical and biological aspects of the ALL are well documented, little is known
about individual susceptibility. Polymorphic variants of several genes, diet, environmental
exposure to carcinogens and individualities of immune system are potential factors that could
be increase predisposition to leukemia. (Buffleret al., 2005) However some speculation exist
about the mechanism of the potential agents carcinogenic that could cause such alterations to
ALL origin.(Smith, 1996; Kamdar et al., 2011)
Polymorphisms in the via of folate metabolism
The genetic regulation of folate metabolism have been the focus of many investigations that
may influence in the preleukemic clone origin, by the via DNA hypomethylation of key reg‐
ulatory genes, as well as uracil misincorporation into DNA leading to double-strand breaks
and chromosomal aberrations.(Kamdar et al., 2011) The presence of some polymorphisms in
genes involved in folate metabolism (MTHFR, MTR, CBS, SHMT1 and TYMS) may cause de‐
ficiency in the enzyme activity and lead to inadequate folate metabolism and hypomethylation
of DNA, which may lead to a neoplastic process. (Sharp and Little, 2004; Kamdar et al., 2011)
The insufficient input of folate produces elevated plasma concentration of Homocysteine (Hcy)
and adenosylmethionine (SAM) elevation, so that SAM is inhibitor methyltransferase enzyme.
(Sharp et al., 2004) This inhibition may alter both, the DNA methylation process, and the reg‐
ulation of gene expression. (Sharpand Little, 2004; Lightfoot et al., 2010) The hypomethylation
is associated with activation of oncogenes and neoplastic processes, whereas the hyperme‐
thylation of CpG islands in promoter regions, of some tumor suppressor genes, prevents the
transcription and promotes the development of tumors. (Das and Singal, 2004) (figure 4) As‐
sociations studies have been developed to identify genetic variants associated with ALL sus‐
ceptibility, among them are: methylenetetrahydrofolatereductase (MTHFR), an enzyme that
participates in Hcy and folate metabolism, plays an important role in DNA methylation and
provision of nucleotides for DNA synthesis. (Robien and Ulrich, 2003)
Variations in the MTHFR gene sequence may result in enzymatic deficiency, low plasma folate
levels and hyperhomocysteinemia, a risk factor for many diseases as: coronary diseases, neural
tube defects, cancer, and leukemia, among others. (Lordelo et al, 2011) Association studies
have been described between C677T and A1298C MTHFR polymorphisms and risk of leuke‐
mia (Skibola et al, 1999; Franco et al., 2001; Robien and Ulrich, 2003; Gallegos et al, 2008), which
produces an decreased catalytic activity of MTHFR and subsequent availability of 5,10-MeTHF
and SAM, have been extensively studied in relation to childhood leukemia, these findings have
been inconsistent and their frequency vary among ethnic groups.(Robien and Ulrich, 2003)
Methionine synthase (MTR): Other studied polymorphisms, in association with ALL, are the
missense polymorphism MTR c.2756A>G (D919G), that has been reported that alter the sus‐
ceptibility to various cancers, (Linnebank et al, 2004; Yu et al, 2010) however the results have
been contradictories. MTR is a vitamin B12-dependent enzyme, which catalyzes the remethy‐
lation of Hcy to methionine and the demethylation of 5-meTHF to THF, and has influence on
DNA methylation, as well as on nucleic acid synthesis (Greene, 2010) (figure 4). A meta-anal‐
ysis including 24896 cancer patients and 33862 controls, from 52 published papers, for MTR
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A2756G was reviewed. Overall, individuals carrying MTR 2756GG genotype had a reduced
cancer risk, under a recessive genetic model, in European populations. However, in Asian
populations, it has a significantly high association. In stratified studies by tumor site, there
was a statistically significant reduced risk with ALL. (Yu et al, 2010)
Cystathionine-β-synthase (CBS; gene localized to 21q22.3), the polymorphism most studied
with leukemia are T833C, that co-segregates with 844ins68, and the G919A. (Ge et al, 2011) The
frequencies of these polymorphisms are variable depending of the studied populations. The
CBS participate in the trans-sulfuration pathway, catalyzes the condensation of serine and Hcy
to form cystathionine, an intermediate step in the synthesis of cysteine. (figure 4) The 844ins68
polymorphism was associated in Down Syndrome (DS) with leukemia myeloblasts, detecting
a 4.6-fold higher rate (P < 0.001) when compared to non-DS individuals. (Ge et al, 2011) The
biological function of this polymorphism is even contradictory, it has been demonstrated that
carriers of 844ins68 have significantly lower total plasma Hcy levels, after a methionine load,
and concluded that this polymorphism was associated with higher CBS enzyme activities. (Ge
et al, 2011)
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Figure 4. Polymorphisms (MTHFR, CBS and TS) of the via of folate in the development of ALL
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Serine Hydroxymethyltransferase 1 (SHMT1)
Cytosolic SHMT1 regulates 5,10-MeTHF,that acts as substrate for MTHFR. The 1420C>T poly‐
morphism of this gene reduces circulating folate levels, and may mimic folate deficiency, con‐
sequently shunting 5,10-MeTHF towards DNA synthesis, and have been shown that moderate
the risk of hematological malignancies. (Lightfoot et al, 2005) Folate is a component important
in the development of the embryogenesis and early fetal development, via its effects on DNA
methylation and synthesis. Then, the well-documented in utero origin of ALL has led to hy‐
pothesize that deficient folate intake may be important in its etiology. (Lightfoot et al, 2005; de
Jonge et al, 2009)
Thymidylate Synthase (TYMS)
Thymidylate synthase (TS) has been shown to moderate the risk of hematological malignan‐
cies. (Valiket al, 2004; Lightfoot et al, 2005) Although, it has been proposed that arise by genetics
and environmental factors. (Krajinovic et al, 2004) Consistent with this paradigm, variants of
genes involved in xenobiotic metabolism, DNA repair pathway and cell cycle checkpoint
functions, have been shown to influence the susceptibility to ALL. (Pui, 2009) Many enzymes
are involved in the folate metabolism, among which, thymidylate synthase (TS) is a crucial
enzyme and hence a good candidate for studying the effect of polymorphisms in the folate
metabolism gene, on the development of malignancies. TS, encoded by the TS, gene located
on chromosome 18p11.32, plays a vital role in maintaining a balanced supply of deoxynucleo‐
tides, required for DNA synthesis and repair, by catalyzing the conversion of dUMP to dTMP.
(Nazki et al, 2012)
The polymorphisms in TYMS gene include a 6-bp deletion (1494del6), in the 3′-untranslated
region of TS that influences RNA levels; and a polymorphic tandem 28-bp repeat sequence
within the promoter enhancer region of TS, where the triple repeat increases gene expression
levels and reduces DNA damage. In fact, it is thought that the input of deoxynucleotides for
DNA synthesis is controlled by TYMS, which has a polymorphic tandem repeat sequence
within the promoter enhancer region containing a double (2R)or triple (3R) 28–bp repeat. The
presence of the triple repeat leads to increased levels of gene expression and a reduction in
DNA damage. (Skibola et al, 2004; Lightfoot et al, 2010) Methotrexate, an antifolic acid agent,
has demonstrated to be an effective chemotherapeutic drug for the treatment of lymphoid
malignancies, indicating an association between the folate metabolism and the development
of such malignancies. (Hishidaet al, 2003) This increased expression may, in turn, increase the
conversion of dUMP to dTMP, thereby; decreasing uracil levels and the consequent erroneous
incorporation of uracil into DNA of rapidly dividing hematopoietic stem cells, and could work
protectively against the development of ALL. (Skibola et al, 2004) The TS 28-bp repeat poly‐
morphism has been shown to modulate the risk of ALL in various populations, but the ob‐
tained results are controversial and require further investigation to be confirmed and clarified.
(Skibola et al, 2004; deJonge et al, 2009)
Polymorphisms in the xenobiotics metabolism
An ability that man has acquired in the course of evolution is the way to metabolize foreign
compounds for the body to facilitate disposal. These compounds are called xenobiotics, in food
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and the environment are mostly lipophilic, so it tends to accumulate in lipophilic environments
the body and are difficult to remove so they tend to trigger toxicity phenomena. (Gonzalez
and Gelboin, 1994) The liver removes lipophilic xenobiotics, through a set of known reactions
of biotransformation. The end result is the formation of metabolites less lipophilic and more
soluble, which are easily eliminated in the urine or bile compounds. That is why these reactions
are known as detoxification or deactivation. (DeAnn, 1998) In this sense, drugs are a class of
compounds that are absorbed xenobiotics on the body and distributed in body fluids, tissue
and organ. Where exert their pharmacological action and pharmacodynamics specified; only
a small part reaches the tissue-receptor-target enzyme, while most are metabolized and elim‐
inated. (Sheweita, 2000) Moreover, the processes of biotransformation of xenobiotics are sub‐
divided into two phases: phase I metabolism, carried out by two families of enzymes
oxygenases: those dependent on cytochrome P450 (CYP450) monooxygenases and the flavin
(FMO). Their metabolism is characterized by the action of chemical processes of different na‐
ture mainly oxidation, oxygenation, reduction and hydrolysis, so as dealquilations and deha‐
logenations. These chemical reactions produce metabolites capable of binding covalently to
endogenous molecules such as glucuronic acids, glutathione, sulfate and amino acids that
generate conjugates, which are metabolized by Phase II which is characterized by solubility in
generating molecules and decreased toxicity, generated by the modification of new functional
groups, which transform the more polar metabolite, which facilitates their removal. In this
regard, when a drug enters the body usually is modified by conjugation reactions to be easily
removed. However, when there modifications in the concentrations concentration (high or
low) of enzymes that perform the conjugation process and if the xenobiotic is lipophilic nature,
tends to accumulate in the cell, which will lead to different processes: 1) accumulation of re‐
active metabolites adduct forming with DNA, 2) formation of a toxic compound 3) a nontoxic
compound becomes a toxic derivative. This generates secondary metabolic pathways may
have a carcinogenic action, toxicological, genotoxic or mutagenic in the body. (Marmiroli and
Maestri, 2008) Different studies in the literature have suggested the association of polymor‐
phisms in genes involved in xenobiotic metabolism phase I and II in patients with leukemia.
(Aydin et al, 2006; Gallegos et al,2008, Lordelo et al, 2011)
Secondary leukemias
Secondary hematological malignancies represent a serious complication of cancer treatment.
Usually manifiest as acute leukemia and MDS, and known more about these could eventually
help reduce its appearance (Levine and Blomifield, 1992). It is known that this type of leuke‐
mias may arise as a result of exposure to cytotoxic treatments (with genotoxicity secondary
effects) and/or radiotherapy (RT) and as a result of other hematological disorders (Harris et
al, 1999; Brunning et al, 2001), and possibly also, product of environment or genetic causes.
(Levine and Blomifield, 1992) In most cases it is proposed that the mechanism of leukemo‐
genesis is associated with DNA damage in hematopoietic cells of the bone marrow by agents
such as those used in chemotherapy (CT). (Levine and Blomifield, 1992) Although most sec‐
ondary leukemias are acute AML, there have been reports of lymphoid leukemia and CML is
associated with CT. (Andersen et al, 2000; Krishnan et al, 2000; Pedersen-Bjergaard et al, 2002)
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The AML are hematologic malignancies characterized by the uncontrolled myeloid blast pro‐
liferation in the bone marrow and in peripheral tissues. (Sevilla et al, 2002) Differ according to
the cytological, immunophenotypic and cytogenetic characteristics. (Paietta, 1995; Head, 1996)
On the other hand the MDS are dis-hematopoietics processes of bone marrow, characterized
by alteration in the maturation and differentiation of hematopoietic cell lines (with involve‐
ment of one, two or all three blood cell lineages) and in some cases, by the presence of bone
marrow blasts, without showing acute leukemia criteria. (Bennet et al, 1982; Cheson, 1997)
The term secondary leukemia has referred to the development of AML as result of CT treat‐
ment, particularly alkylating agents (Levine and Blomifield, 1992) or topoisomerase II inhib‐
itors, RT, or by exposure to environmental carcinogens (Harris et al, 1999; Brunning et al,
2001). Within the term of secondary acute leukemias (SAL) different entities are grouped
by etiopathogenesis,  prognosis and response to therapy. In general can be distinguished
two groups: those that are a result of exposure to cytotoxic treatments such as CT and/or
RT and those that are a result of the final evolution of other hematological disorders, such
as, myeloproliferative syndromes, MDS, paroxysmal nocturnal hemoglobinuria. (Harris et
al, 1999; Brunning et al, 2001)
In close relationship with these two groups of SAL also found leukemias result from environ‐
mental or occupational exposure to carcinogens, (Levine and Blomifield, 1992) or those that
develop in patients with genetic disorders as chromosomal fragility syndromes such as Fan‐
coni anemia and Bloom syndrome (Popp and Bohlander, 2010)
The increase is due to the increased number of survivors of other forms of cancer, (Ng et al,
2000) is important to know more about SAL, especially AML or MDS relating to previous
therapies (AML-PT, MDS-PT). The cumulative risk of developing AML-PT/MDS-PT after ten
years of receiving CT for breast cancer, non-Hodgkin´s lymphoma, ovarian cancer or Hodgkin
´s disease, has been estimated at 1.5, 7.9, 8.5, and 3.8% respectively. (Bolufer et al, 2006) More‐
over, generally the cases of AML-PT/MDS-PT, the primary disease may be a solid tumor, other
haematological malignancy or non-malignant disorder.
Today it is clear that AML-PT/MDS-PT can develop after exposure to cytotoxic CT with alky‐
lating agents, topoisomerase II inhibitors, and/or RT, for the treatment of other neoplasias or
in treating non-malignant disorders. In this sense, has been described after the use of immu‐
nosuppressants such as azathioprine (Harris et al, 1999; Brunning et al, 2001). While the study
of these entities has been important, the maximum latency between exposure to leukemogenic
agent and the development of AML-PT/MDS-PT has not been established with certainty.
Due to history of exposure to certain agents and the association with some cytogenetic abnor‐
malities characteristic, two groups are recognized in AML-PT/MDS-PT: (Harris et al, 1999;
Brunning et al, 2001)
Which appears as a result of the mutagenic effect of alkylating agents treatment, ionizing ra‐
diation or both, that occur after a long latency period between 5 to 7 years of exposure to
cytotoxic agents and often show a phase of myelodysplasia prior to the evolution to AL, and
often show a phase of myelodysplasia prior to the evolution to AL, which often produce al‐
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terations of chromosomes 5 and 7, (-5/5q- and -7/7q-) frequently refractory to treatment. (An‐
dersen and Pedersen, 2000)
Those in patients treated with drugs that inhibit DNA-topoisomerase II as epipodophyllotox‐
ins and anthracyclines, with a short latency period of between 2 to 3 years, without prior
myelodysplasia phase and in which observed balanced translocations as 11q23 (MLL) and
21q22 (AML1/RUNX1), although there are some discrepancies. The treatment response is not
significantly different from those of patients with de novo AML. (Penderse, 2002)
Leukemias have been associated with exposure to various agents as benzene and its metab‐
olites (phenol, hydroquinone), environmental carcinogens demonstrated relationship to in‐
creased  risk  of  developing  leukemia.  (Lan  et  al,  2004)  Other  compounds  studied  with
controversial relationship, are some agricultural pesticides, heavy metals, smoke snuff, alco‐
hol intake and exposure to cosmic rays of airlines pilots. (Larson, 2007) Ionizing radiation
is a known leukemogenic agent and the main action mechanism includes the breakage of
the DNA strands which can cause the aforementioned chromosomal deletions and translo‐
cations. Breaks may result from a direct effect of high doses of radiation or indirectly by
free radicals generation. Furthermore, ionizing radiation can induce changes of bases in the
DNA sequences,  crosslinking strands,  multiple damages or epigenetic  alterations (Finch,
2007). In the case of RT, induced leukemia seems to start in the first 5 years after expo‐
sure, peaks at 10 years and decreases significantly after 15 years. The relative incidence of
leukemias by RT is dose dependent, duration of exposure, and area of exposed bone mar‐
row. (Finch, 2007) Fractionated doses of radiation are less leukemogenic than higher sin‐
gle doses, because it allows greater efficiency of DNA repair mechanisms. The leukemogenic
risk appears  to  be greater  when low-dose exposure affects  large areas of  bone marrow,
whereas high doses of radiation over limited areas appear to have less effect. This is attrib‐
uted to increased apoptosis induced by high doses of radiation on cells exposed. (Inskip,
1999; Smith et al, 2002) Estimates show, that patients undergoing RT for the treatment of
malignancies or other non-malignant diseases has a risk of two to three times more to de‐
velop AML-PT/MDS-PT. (Smith et al, 2002) On the other hand, a younger ages at the time
of  exposure,  greater  the  leukemogenic  risk.  The increased risk  for  developing AML-PT/
MDS-PT, after treatment of non Hodkin lymphomas, breast cancer, cervical cancer and ute‐
rine body and Ewing’s sarcoma, is attributed to the use of RT, while associated with Hodg‐
kin’s disease, ovarian cancer and testicular cancer, has been associated with the use of CT.
(Levine and Blomifield, 1992; van Leeuwen et al, 1994; Inskip, 1999; Smith et al, 2002)
Many drugs used as CT in the treatment of a primary cancer, have been linked to the subse‐
quent development of AML-PT/MDS-PT, thus, alkylating agents were the first to be evidenced
leukemogenic potential, (Pedersen, 2002) effect related to the cumulative dose of the drug, the
effect being greater with increasing patient age (Pedersen, 2002). All alkylating agents have
effect leukemogenic, such is the case of drugs such as mechlorethamine, procarbazine, chlor‐
ambucil, cyclophosphamide, melphalan, semustine, lomustine, carmustine, prednimustine,
busulfan. However, although the relative risk leukemogenic of these drugs has not been de‐
finitively established, drugs such melphalan and busulfan seem to condition an increased riesk
than others as cyclophosphamide for reason which are unknown. (Stott et al, 1977; Greene et
Pathophysiology of Acute Lymphoblastic Leukemia
http://dx.doi.org/10.5772/54652
61
al, 1986; Krishnan et al, 2000) Although, this seems to suggest that more genotoxic and cytotoxic
drugs are chosen that have less leukemogenic potential. Alkylating agents besides the afore‐
mentioned chromosomal damage can cause point mutations in some oncogenes like RAS.
(Pedersen et al, 1988) However, these effects are no restricted to certain genes or chromosomal
regions and possibly the selection of cells with abnormalities of chromosomes 5 and 7 come
conditioned by a proliferative advantage to cells carrying these alterations. (Johansson et al,
1991; de Greef and Hagemeiger, 1996; Andersen et al, 2000)
Meanwhile, drugs that act by inhibiting topoisomerase II, as the epipodophyllotoxins (etopo‐
side and teniposide) ( et al, 1999) and intercalating agents such as anthracyclines (doxorubicin,
daunorubicin, idarubicin) o las anthracenediones (mitoxantrone), have been associated with
balanced translocations that originates function genes. The most common affect 11q23, 21q22,
inv(16) and t(15;17) (Andersen et al, 1998; Rowley and Olney, 2002). Recently high-dose CT
followed by autologous hematopoietic transplantation, have been associated with the devel‐
opment of AML-PT/MDS-PT, with time of onset of 47-50 months after transplantation. (Na‐
demanee et al, 1995; Traweek et al, 1996; Krishnan et al, 2000; Pedersen et al, 2000; Gilliland
and Gribben, 2002)
An important point to consider is individual susceptibility, since only a minority of patients
develop secondary leukemia after exposure to CT, therefore it is suggested that differences in
drug metabolism may predispose to the development of AML-PT/MDS-PT of some patients.
(Bolufer et al, 2006) In this way, polymorphisms of genes encoding enzymes involved in drug
metabolism could contribute to the risk of developing these pathologies. These genes could
explain differences in metabolizing of these agents and condition a lower detoxification ca‐
pacity or repair of genetic damage induced by the drug. (Bolufer et al, 2006) Genes have been
studied encoding cytochrome P450 (CYPs) related to phase I metabolism, glutathione S-meth‐
yltransferase (GSTT1, GSTM1, GSTP1) involved in phase II metabolism (conjugation/detoxi‐
fication), the NAD(P)H: qinone oxo-reductase 1 (NQO1) which acts on the metabolism of free
radicals and oxidative stress, genes related to folate metabolism (MTHFR, TYMS, SHMT1,
MTRR), also involved in DNA synthesis and genes related to DNA repair (hMLH1, hMSH2,
hMSH3, RAD51, XRCC1, XRCC3, XPD, XPG, CHEK2, and ATM) that can cause genomic in‐
stability. (Bolufer et al, 2006)
The AML-PT/MDS-PT pathogenesis includes clonal alterations in the some genes function due
to single mutations, chromosomal abnormalities or epigenetic phenomena. Many of the altered
genes are tumor suppressor that have a recessive character and therefore, requires the loss of
both alleles. The loss of a single copy of the gene can result in reduction of gene products and
predispose to malignancy. Current evidence indicates that AML results from at least two mu‐
tations classes. The class I, confers proliferative advantage and/or cell survival without affect‐
ing their differentiation capacity, while the class II, prevent the normal hematopoietic cell
differentiation. (Deguchi and Gilliland, 2002)
The AML-PT represent 10 to 15% of total AML and its incidence is increasing substantially in
recent years, (Ng et al, 2000) the AML-PT are often associated with clonal cytogenetic abnor‐
malities similar to those found in newly diagnosed AML, but with higher incidence of poor
prognosis karyotypes and have particular clinical and biological features that include a poor
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response to CT commonly used in the treatment of AML and therefore have a significantly
adverse prognosis.
Different authors have been relationship to drugs and radiation with specific emphasis on the
balanced rearrangements chromosomes. (Andersen et al, 1998) Increased frequency of dicen‐
tric chromosomes in therapy-related MDS and AML compared to de novo disease is signifi‐
cantly related to previous treatment with alkylating agents and suggests a specific
susceptibility to chromosome breakage at the centromere. (Andersen and Pedersen, 2000)
3. Conclusion
In this way one can conclude that the pathophysiology of acute lymphoblastic leukemia is very
complex and involves various factors (genetic, immunes, environmental, and drugs) at dif‐
ferent levels, and also has a close and complex relationship. The key features in the patho‐
physiology of the ALL is its monoclonal origin, uncontrolled cell proliferation by sustained
self-stimulation of their receptors for growth, no response to inhibitory signals, and cellular
longevity conditioned by decreased apoptosis.
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